The defining DNA methylation signature of Floating-Harbor Syndrome

  title={The defining DNA methylation signature of Floating-Harbor Syndrome},
  author={Rebecca L. Hood and Laila Cigana Schenkel and Sarah M. Nikkel and Peter J. Ainsworth and Guillaume Par{\'e} and Kym M. Boycott and Dennis E. Bulman and Bekim Sadikovic},
  journal={Scientific Reports},
Floating-Harbor syndrome (FHS) is an autosomal dominant genetic condition characterized by short stature, delayed osseous maturation, expressive language impairment, and unique facial dysmorphology. We previously identified mutations in the chromatin remodeling protein SRCAP (SNF2-related CBP Activator Protein) as the cause of FHS. SRCAP has multiple roles in chromatin and transcriptional regulation; however, specific epigenetic consequences of SRCAP mutations remain to be described. Using high… 

Identification of epigenetic signature associated with alpha thalassemia/mental retardation X-linked syndrome

Most significant methylation changes in the 14 genomic loci provide a unique epigenetic signature for this syndrome that may be used as a highly sensitive and specific diagnostic biomarker to support the diagnosis of ATR-X, particularly in patients with phenotypic complexity and in patientswith ATRX gene sequence variants of unknown significance.

The defining DNA methylation signature of Kabuki syndrome enables functional assessment of genetic variants of unknown clinical significance

A “methylation variant pathogenicity (MVP) score” is developed, which enables 100% sensitive and specific identification of individuals with Kabuki syndrome and illustrates that DNA methylation patterns can be interpreted as ‘epigenetic echoes’ in certain clinical disorders.

Detection of a DNA Methylation Signature for the Intellectual Developmental Disorder, X-Linked, Syndromic, Armfield Type

The peripheral blood specimens in a cohort of individuals with MRXSA were assessed and a unique and highly specific DNA methylation episignature associated with this disorder was detected and used to construct a support vector machine model capable of sensitive and specific identification of Individuals with pathogenic variants in FAM50A.

Gene domain-specific DNA methylation episignatures highlight distinct molecular entities of ADNP syndrome

This work describes the first Mendelian condition with two distinct episignatures caused by mutations in a single gene, which enable diagnosis, screening, and genetic variant classifications in ADNP syndrome.

Peripheral blood epi-signature of Claes-Jensen syndrome enables sensitive and specific identification of patients and healthy carriers with pathogenic mutations in KDM5C

Peripheral blood epi-signature in Claes-Jensen syndrome can be used for molecular diagnosis and carrier identification and assist with interpretation of genetic variants of unknown clinical significance in the KDM5C gene.

Deficiency of TET3 leads to a genome-wide DNA hypermethylation episignature in human whole blood

This work expands the role of epi-phenotyping in molecular diagnosis and reveals genome-wide DNA methylation profiling as a quantitative, functional readout for characterization of this new biochemical category of disease.

DNA methylation signatures in mendelian developmental disorders as a diagnostic bridge between genotype and phenotype.

This work proposes that DNA methylation signatures in patients clinically diagnosed with syndromes manifesting as developmental disabilities with intellectual impairments be considered as echoes and/or legacies of the initiating mutational events within proteins of the so-called epigenetic machinery.

Identification of a DNA Methylation Episignature in the 22q11.2 Deletion Syndrome

Mapping the 22q11.2DS DNA methylation episignature provides both novel insights into the molecular pathogenesis of this disorder and an effective tool in the molecular diagnosis of 22q 11.2 DS.



NSD1 mutations generate a genome-wide DNA methylation signature

It is proposed that pathogenic NSD1 mutations have a genome-wide impact on the most stable epigenetic mark, DNA methylation (DNAm), and by interrogating DNAm in SS patients, this work identifies a highly specific and sensitive NSD 1+/− signature, which encompasses genes that function in cellular morphogenesis and neuronal differentiation, reflecting cardinal features of the SS phenotype.

Identification of a methylation profile for DNMT1-associated autosomal dominant cerebellar ataxia, deafness, and narcolepsy

This report identifies robust changes in the DNA methylation patterns in ADCA-DN patients, which is an important step towards elucidating disease pathogenesis.

DNA methylation analysis in constitutional disorders: Clinical implications of the epigenome

An overview of epigenetic mechanisms with a focus on DNA modifications, including the molecular mechanisms of DNA methylation and subtypes of DNA modifications are presented, and the classic and emerging genomic technologies that are being applied to this study are described.

Multilocus loss of DNA methylation in individuals with mutations in the histone H3 Lysine 4 Demethylase KDM5C

Genetic alterations in patient samples carrying a mutation in a gene involved in the regulation of histone modifications are identified, for the first time, and support the concept that DNA methylation and H3 lysine 4 methylation are functionally interdependent.

Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP

It is proposed that the loss of one functional copy of the CBP gene underlies the developmental abnormalities in RTS and possibly the propensity for malignancy.

Genetic heterogeneity in Rubinstein-Taybi syndrome: mutations in both the CBP and EP300 genes cause disease.

There is a direct link between loss of acetyl transferase activity and RSTS, which indicates that the disorder is caused by aberrant chromatin regulation and the search for mutations to the EP300 gene was extended and showed that mutations in EP300 also cause this disorder.

The phenotype of Floating–Harbor syndrome in 10 patients

Clinical findings in 10 typically affected individuals ranging in age from 7 to 34 years and a mother and daughter who display some features of FHS are reported and microarray analysis in eight of the patients provided no evidence that FHS is caused by a large‐scale copy‐number genomic change.